MM cells were found to express ultralow levels of CD1924,99, and CD19 CAR-T therapy for treating MM resulted in a durable CR >1 year, despite the absence of CD19 expression post-CD19 CAR-T cell infusion24. Here, CD19 is linked to Miyoshi myopathy.